Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07446257 | THIO and Cadonilimab in Resectable Hepatocellular Carcinoma | EARLY_PHASE1 | NOT YET_RECRUITING | 60 | — | — | May 1, 2026 | May 1, 2031 | Mar 3, 2026 | 1 | United States |
Safety is measured as the proportion of participants who experience a treatment-related delay in the planned surgical resection, defined as surgery occurring more than 28 days after the expected surgery date (day 5 of cycle 3 for all treatment arms)
| Arm | Type | Description |
|---|---|---|
| Arm A: Ateganocine + Cadonilimab | EXPERIMENTAL | Ateganosine: 60 mg/day (180 mg/cycle) IV over 30 minutes±5 minutes Cadonilimab: 10 mg/kg IV over 60 minutes±5 minutes |
| Arm B: Ateganocine | EXPERIMENTAL | Ateganosine: 60 mg/day (180 mg/cycle) IV over 30 minutes±5 minutes |
| Arm C: Cadonilimab | EXPERIMENTAL | Cadonilimab: 10 mg/kg IV over 60 minutes±5 minutes |
| Name | Type | Description |
|---|---|---|
| ateganosine | DRUG | ateganosine: 180 mg IV D1, D2, D3 of 21-day cycle |
| Cadonilimab | DRUG | cadonilimab: 10 mg/kg IV D5 of 21-day cycle |
Inclusion Criteria: 1. Diagnosis of HCC confirmed by histology or according to the American Association for the Study of Liver Disease (AASLD) criteria a. Availability of tumor tissue samples prior to the first day of study treatment is required for all patients. 2. HCC that is amenable to R0 r...